Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cannabis products at the heart of new deal
November 2018
SHARING OPTIONS:

VICTORIA, British Columbia—A new research agreement was established in October between Emerald Health Therapeutics Inc. and VivaCell Biotechnology Spain S.L.U., under which VivaCell will make its CRO services available to Emerald to help clarify mechanisms of action in formulations and dosage forms of cannabis products being developed by Emerald. Financial details were not released.
 
“Emerald’s focus on scientific innovation has the potential to produce a future product pipeline of next-wave cannabis products that fit the needs and preferences of both adult-use consumers and patients,” said Mari-Luz Bellido, managing director of VivaCell. “We believe that cannabis has the potential to be developed into consistent, high-value downstream products. We are pleased to support the development of Emerald’s intellectual property by employing our deep cannabis research experience and conduct[ing] rigorous preclinical studies."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.